Caffeine Clinical Trial
Official title:
Changes in Diaphragmatic Activity Before and After Caffeine Citrate Administration and Discontinuation
Caffeine citrate, the first-line agent for apnea of prematurity, enhances diaphragmatic activity. EDI values of neurally adjusted ventilatory assist (NAVA) modes can be used to quantify the diaphragmatic activity triggered by electrical impulse from the respiratory center. This study aims to evaluate the EDI changes following caffeine citrate administration and cessation in preterm infants, and whether such changes are affected by different doses used variably in clinical settings.
Caffeine citrate has been used as the first-line agent for apnea of prematurity. It works via mechanisms including stimulation of the respiratory center in medulla, increasing sensitivity to carbon dioxide retention, and increment in diaphragmatic activity. The effect of caffeine citrate has been evaluated largely based on parameters concerning clinical symptoms (e.g., decrease in the number of apnea, extubation success, decreased incidence of bronchopulmonary dysplasia) but not quantified parameters of actual diaphragmatic activity. Also, while usual doses of caffeine administration is described in the literature, consensus on the effect of caffeine citrate depending on different dosages has not been established. The current study aims to evaluate effect of caffeine citrate by quantifying the electrical impulses of diaphragmatic activity using EDI values captured from neurally adjusted ventilatory assist (NAVA) mode. Out of preterm infants necessitating invasive or non-invasive ventilators, those who are supported by invasive or non-invasive NAVA would be recruited. EDI changes would be monitored for the following timepoints: at the administration of caffeine citrate loading dose, 1st maintenance dose after loading, and at cessation of caffeine citrate. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06038903 -
The Turkish Version Of The Brief-Caffeine Expectancy Questionnaire
|
||
| Completed |
NCT02900261 -
Study on Sodium and Caffeine in Children and Adolescents
|
||
| Completed |
NCT03850275 -
The Effects of e+Shots Energy Beverage on Mental Energy
|
N/A | |
| Completed |
NCT01924481 -
Effects of a Cocoa Shot on the Human Brain
|
N/A | |
| Completed |
NCT01330680 -
Genetic Determinants of Cardiovascular Response to Coffee Drinking
|
N/A | |
| Completed |
NCT00184912 -
The Effect of Caffeine on Ischemic Preconditioning
|
N/A | |
| Completed |
NCT03859882 -
Protocol PERCAF 2018
|
N/A | |
| Completed |
NCT02832401 -
The Impact of Caffeine on Cognition in Schizophrenia
|
N/A | |
| Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
| Recruiting |
NCT05503732 -
Effects of Energy Drinks on Sleep and Cardiovascular Health
|
N/A | |
| Not yet recruiting |
NCT05521386 -
The Effects of Caffeine on Heart Rate and Heart Rate Variability
|
N/A | |
| Completed |
NCT06039358 -
Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects
|
N/A | |
| Active, not recruiting |
NCT04547868 -
Can Coffee/Caffeine Improve Post-Operative Gastrointestinal Recovery
|
N/A | |
| Completed |
NCT05559372 -
Energy Drink Effects on Performance, Mood, and Cardiovascular Outcomes
|
N/A | |
| Completed |
NCT01783561 -
Early Versus Routine Caffeine Administration in Extremely Preterm Neonates
|
Phase 4 | |
| Completed |
NCT04852315 -
Acute Caffeine Ingestion on Futsal Performance
|
N/A | |
| Completed |
NCT05975489 -
Genetics in the Effect of Caffeine on Fat Oxidation
|
N/A | |
| Recruiting |
NCT03298347 -
Caffeine for Preterm Infants With Apnea of Prematurity(AOP)
|
N/A | |
| Completed |
NCT01435486 -
Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants
|
N/A | |
| Completed |
NCT04869176 -
Effect of Caffeine on Heart Rate Variability in Newborns
|
N/A |